copaydosingefficacyresourcesafety

THIS SITE IS INTENDED FOR US AUDIENCES ONLY

‹

Efficacy

Results from Otezla® (apremilast) clinical trials
  • PASI-75 
    Response
  • PASI
    Scores
  • Scalp Response
    at Week 16
  • Nail Response
    at Week 16
  • Pruritus VAS Scores
  • DLQI Scores
  • 3-year Data
  • LIBERATE: Biologic-naïve
  • Patient
    Photos    Button to view photographs of patients before and after treatment with Otezla® (apremilast)

OTEZLA DEMONSTRATED A SIGNIFICANT INCREASE IN PASI-75 RESPONSE AT WEEK 161-3

ESTEEM® 1: PASI-75 at week 16 (primary endpoint)1,2

ESTEEM 2: PASI-75 at week 16 (primary endpoint)1,3,4

BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index.

Selected Safety Information

Contraindications

  • Otezla® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions

  • Diarrhea, Nausea and Vomiting: Cases of severe diarrhea, nausea, and vomiting have been reported with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting

MEAN PASI SCORES THROUGH WEEK 322,4

ESTEEM 1: Mean percent change in PASI scores at week 162,4,a-d

Prespecified exploratory analysis; data as observed

aWeek 16: secondary endpoint; all other timepoints: exploratory endpoints. bBaseline mean PASI scores: Placebo, 19; Otezla, 19; Total, 19. cAt week 16, patients receiving placebo were switched to Otezla. dCauses of patient dropout include adverse reactions, lack of efficacy, and patient withdrawal. e95% confidence interval.

BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index.

Selected Safety Information

Warnings and Precautions (cont’d)

  • Depression: Treatment with Otezla is associated with an increase in depression. During clinical trials 1.3% (12/920) of patients reported depression, compared to 0.4% (2/506) on placebo. Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur

SCALP RESPONSE AT WEEK 162,4

ESTEEM 1: Proportion of patients with an ScPGA score of clear or minimal at week 162,4,a-c

Prespecified exploratory endpoint

aFAS; LOCF. bIn the planned hierarchical statistical testing sequence for ESTEEM 1 and ESTEEM 2, efficacy analyses preceding ScPGA were statistically significant, allowing for control of the overall type 1 error rate at 0.05 significance level in analysis of ScPGA. cBaseline ScPGA ≥3.

BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; FAS, full analysis set; LOCF, last observation carried forward; ScPGA, Scalp Physician Global Assessment.

Selected Safety Information

Warnings and Precautions (cont’d)

  • Weight Decrease: Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with Otezla and in 5% (19/382) of patients treated with placebo. Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla

NAIL RESPONSE AT WEEK 162,4

ESTEEM 1: Mean percent change from baseline NAPSI scores at week 162,4,a-c

Prespecified exploratory endpoint

aFAS; LOCF. bIn the planned hierarchical statistical testing sequence for ESTEEM, efficacy analyses preceding NAPSI were statistically significant, allowing for control of the overall type 1 error rate at 0.05 significance level in analysis of NAPSI. cIn patients with nail psoriasis at baseline (NAPSI score ≥1; 66.1% [558/844]).

BID, twice daily; BL, baseline; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; FAS, full analysis set; LOCF, last observation carried forward; NAPSI, Nail Psoriasis Severity Index.

Selected Safety Information

Warnings and Precautions (cont’d)

  • Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

MEAN PRURITUS VAS SCORES THROUGH WEEK 322,4

ESTEEM 1: Mean change from baseline pruritus VAS scores at week 162,4,a-e

Prespecified exploratory analysis; data as observed

aPruritus was measured on a 100-mm VAS. bAt week 16, patients receiving placebo were switched to Otezla. cBaseline mean pruritus VAS scores (mm): Placebo, 65.2; Otezla, 66.2. dWeek 16: secondary endpoint; all other time points: exploratory endpoints. eCauses of patient dropout include adverse reactions, lack of efficacy, and patient withdrawal. f95% confidence interval.

BID, twice daily; BL, baseline; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; VAS, visual analog scale.

Selected Safety Information

Adverse Reactions

  • Adverse reactions reported in ≥5% of patients were (Otezla%, placebo%): diarrhea (17, 6), nausea (17, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4)

CHANGE IN QUALITY OF LIFE AS MEASURED BY DLQI4,5

ESTEEM 1: Mean change from baseline DLQI scores at week 164,5,a-d

Exploratory analysis; data as observed

aAt week 16, patients receiving placebo were switched to Otezla. bBaseline mean DLQI scores: Placebo, 12.1; Otezla, 12.7. cWeek 16: secondary endpoint; all other time points: exploratory endpoints. dCauses of patient dropout include adverse reactions, lack of efficacy, and patient withdrawal. e95% confidence interval.
BID, twice daily; BL, baseline; DLQI, Dermatology Life Quality Index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis.

  • The DLQI is a 10-item questionnaire assessing the impact of skin disease on health-related quality of life (HRQoL). Total score ranges from 0 to 30; higher scores indicate poor quality of life and scores of 11 to 20 indicate a large impact of skin disease on HRQoL. The minimal clinically important difference (MCID) in the DLQI is a decrease of 5.0 points from baseline5

Selected Safety Information

Use in Specific Populations

  • Pregnancy and Nursing Mothers: Otezla is Pregnancy Category C; it has not been studied in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether apremilast or its metabolites are present in human milk. Caution should be exercised when Otezla is administered to a nursing woman

3-YEAR DATA WITH OTEZLA4

ESTEEM 1: PASI-75 response through 156 weeks4,a-e

Prespecified exploratory analysis; data as observed

aFAS. bWeek 16: primary endpoint; all other time points: exploratory endpoints. cRandomized treatment withdrawal phase (weeks 32 to 52) where additional psoriasis therapies, including topicals and/or phototherapy, could have been added to PASI-75 nonresponders. Please see study design for additional information. dData are presented “as observed” with no imputation for missing values; causes of patient dropout include lack of efficacy, withdrawal by subject, adverse events, and loss to follow-up, which may impact the proportion of responders at each time point. eOpen-label extension phase: pooled treatment arms reflect post-hoc analysis.

BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; FAS, full analysis set; PASI, Psoriasis Area and Severity Index.

ESTEEM 1: Mean percent change in PASI scores through 156 weeks4,a-f

Prespecified exploratory analysis; data as observed

aFAS. bWeek 16: secondary endpoint; all other time points: exploratory endpoints. cBaseline mean PASI scores: Placebo, 19; Otezla, 19; total, 19. dRandomized treatment withdrawal phase (weeks 32 to 52) where additional psoriasis therapies, including topicals and/or phototherapy, could have been added to PASI‍-‍75 nonresponders. Please see study design for additional information. eData are presented “as observed” with no imputation for missing values; causes of patient dropout include lack of efficacy, withdrawal by subject, adverse events, and loss to follow-up, which may impact the proportion of responders at each time point. fOpen-label extension phase: pooled treatment arms reflect post-hoc analysis.

ESTEEM 1: Proportion of patients with ScPGA score of clear or minimal through 156 weeks4,a-f

Prespecified exploratory analysis; data as observed

aFAS. bBaseline ScPGA ≥3. cStatistical analyses were conducted in a hierarchical manner for efficacy endpoints, including ScPGA score, to control the overall type 1 error rate. dRandomized treatment withdrawal phase (weeks 32 to 52) where additional psoriasis therapies, including topicals and/or phototherapy, could have been added to PASI-75 nonresponders. Please see study design for additional information. eData are presented “as observed” with no imputation for missing values; causes of patient dropout include lack of efficacy, withdrawal by subject, adverse events, and loss to follow-up, which may impact the proportion of responders at each time point. fOpen-label extension phase: pooled treatment arms reflect post-hoc analysis.

ScPGA, Scalp Physician Global Assessment.

ESTEEM 1: Mean percent change from baseline NAPSI scores through 156 weeks4,a-f

Prespecified exploratory analysis; data as observed

aFAS. bIn patients with nail psoriasis at baseline (NAPSI score ≥1; 66.1% [558/844]). cStatistical analyses were conducted in a hierarchical manner for efficacy endpoints, including NAPSI score, to control the overall type 1 error rate. dRandomized treatment withdrawal phase (weeks 32 to 52) where additional psoriasis therapies, including topicals and/or phototherapy, could have been added to PASI-75 nonresponders. Please see study design for additional information. eData are presented “as observed” with no imputation for missing values; causes of patient dropout include lack of efficacy, withdrawal by subject, adverse events, and loss to follow-up, which may impact the proportion of responders at each time point. fOpen-label extension phase: pooled treatment arms reflect post-hoc analysis.

BL, baseline; NAPSI, Nail Psoriasis Severity Index.

ESTEEM 1: Mean change from baseline pruritus VAS scores through 156 weeks4,a-g

Prespecified exploratory analysis; data as observed

aFAS. bPruritus was measured on a 100-mm VAS. cBaseline mean pruritus VAS scores (mm): Placebo, 65.2; Otezla, 66.2. dWeek 16: secondary endpoint; all other time points: exploratory endpoints. eRandomized treatment withdrawal phase (weeks 32 to 52) where additional psoriasis therapies, including topicals and/or phototherapy, could have been added to PASI-75 nonresponders. Please see study design for additional information. fData are presented “as observed” with no imputation for missing values; causes of patient dropout include lack of efficacy, withdrawal by subject, adverse events, and loss to follow-up, which may impact the proportion of responders at each time point. gOpen-label extension phase: pooled treatment arms reflect post-hoc analysis.

VAS, visual analog scale.

ESTEEM 1: Mean change from baseline DLQI scores through 156 weeks4,a-f

Prespecified exploratory analysis; data as observed

aFAS. bBaseline mean DLQI scores: Placebo, 12.1; Otezla, 12.7. cWeek 16: secondary endpoint; all other time points: exploratory endpoints. dRandomized treatment withdrawal phase (weeks 32 to 52) where additional psoriasis therapies, including topicals and/or phototherapy, could have been added to PASI-75 nonresponders. Please see study design for additional information. eData are presented “as observed” with no imputation for missing values; causes of patient dropout include lack of efficacy, withdrawal by subject, adverse events, and loss to follow-up, which may impact the proportion of responders at each time point. fOpen-label extension phase: pooled treatment arms reflect post-hoc analysis.

DLQI, Dermatology Life Quality Index.

  • The DLQI is a 10-item questionnaire assessing the impact of skin disease on health-related quality of life (HRQoL). Total score ranges from 0 to 30; higher scores indicate poor quality of life and scores of 11 to 20 indicate a large impact of skin disease on HRQoL. The minimal clinically important difference (MCID) in the DLQI is a decrease of 5.0 points from baseline5

Selected Safety Information

Use in Specific Populations (cont’d)

  • Renal Impairment: Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information

EFFICACY IN BIOLOGIC-NAÏVE PATIENTS4,6

LIBERATE®: PASI-75 at week 16 (primary endpoint)6,a

amITT; LOCF.

Patients were randomized and received ≥1 dose of study drug and had both baseline PASI and at least one post-treatment PASI evaluation.

BID, twice daily; LIBERATE, Evaluation in a Placebo-Controlled Study of Oral Apremilast and Etanercept in Plaque Psoriasis; LOCF, last observation carried forward; mITT, modified intent-to-treat; PASI, Psoriasis Area and Severity Index.

In LIBERATE:
  • The most common adverse reactions in ≥5% of patients were nausea, diarrhea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache6
  • Discontinuation of treatment due to adverse reactions was 3.6% for Otezla and 2.4% for placebo6

LIBERATE study design6

Program:

  • Global, phase 3b, placebo-controlled, double-blind, double-dummy study
  • 250 adult patients with moderate to severe plaque psoriasis
  • Click here to see full study design for more information (select LIBERATE Study Design tab)

LIBERATE: Mean percent change in PASI scores at week 164,6,a

Prespecified exploratory analysis; data as observed; mITT

aBaseline mean PASI scores: Placebo, 19.4; Otezla, 19.3. b95% confidence interval.

LIBERATE: Mean change from baseline pruritus VAS scores at week 164,6,a,b

Prespecified exploratory analysis; data as observed; mITT

aPruritus was measured on a 100-mm VAS. bBaseline mean pruritus VAS scores (mm): Placebo, 62.5; Otezla, 62.6. c95% confidence interval.

BL, baseline; VAS, visual analog scale.

LIBERATE: Mean improvement from baseline DLQI scores at week 164,6,a

Secondary endpoint; data as observed; mITT

aBaseline DLQI scores: Placebo, 11.4; Otezla, 13.6. b95% confidence interval.

DLQI, Dermatology Life Quality Index.

  • The DLQI is a 10-item questionnaire assessing the impact of skin disease on health-related quality of life (HRQoL). Total score ranges from 0 to 30; higher scores indicate poorer quality of life and scores of 11 to 20 indicate a large impact of skin disease on HRQoL. The minimal clinically important difference (MCID) in the DLQI is a decrease of 5.0 points from baseline5

Selected Safety Information

Contraindications

  • Otezla® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions

  • Diarrhea, Nausea and Vomiting: Cases of severe diarrhea, nausea, and vomiting have been reported with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting

Results seen in Otezla patients4

Individual results may vary.

Actual patient PASI-52 result with Otezla® (apremilast) at baseline

Baseline

Actual patient PASI-52 result with Otezla® (apremilast) after 16 weeks

Week 16

ESTEEM 1: PASI-52 result*

Actual patient PASI-69 result with Otezla® (apremilast) at baseline

Baseline

Actual patient PASI-69 result with Otezla® (apremilast) after 16 weeks

Week 16

ESTEEM 1: PASI-69 result*

Actual patient PASI-75 result with Otezla® (apremilast) at baseline

Baseline

Actual patient PASI-75 result with Otezla® (apremilast) after 16 weeks

Week 16

PASI-75 result

Actual patient PASI-76.5 result with Otezla® (apremilast) at baseline

Baseline

Actual patient PASI-76.5 result with Otezla® (apremilast) after 16 weeks

Week 16

PASI-76.5 result

Actual patient PASI-80 result with Otezla® (apremilast) at baseline

Baseline

Actual patient PASI-80 result with Otezla® (apremilast) after 16 weeks

Week 16

PASI-80 result

Actual patient PASI-85 result with Otezla® (apremilast) at baseline

Baseline

Actual patient PASI-85 result with Otezla® (apremilast) after 16 weeks

Week 16

ESTEEM 1: PASI-85 result*

Actual patient PASI-63 result with Otezla® (apremilast) at baseline

Baseline

Actual patient PASI-63 result with Otezla® (apremilast) after 16 weeks

Week 16

ESTEEM 1: PASI-63 result*

*Actual clinical trial patient.

ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index.

Selected Safety Information

Warnings and Precautions (cont'd)

  • Depression: Treatment with Otezla is associated with an increase in depression. During clinical trials 1.3% (12/920) of patients reported depression, compared to 0.4% (2/506) on placebo. Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur

References: 1. Otezla [package insert]. Summit, NJ: Celgene Corporation. 2. Papp K, Reich K, Leonardi CL, et al. J Am Acad Dermatol. 2015;73(1):37-49. 3. Paul C, Cather J, Gooderham M, et al. Br J Dermatol. 2015;173(6):1387-1399. 4. Data on file, Celgene Corporation. 5. Thaçi D, Kimball A, Foley P, et al. J Eur Acad Dermatol Venereol. 2017;31(3):498-506. 6. Reich K, Gooderham M, Green L, et al. J Eur Acad Dermatol Venereol. 2017;31(3):507-517.

Indications & Important Safety Information

Please click here for Full Prescribing Information.

You are leaving the Otezla® (apremilast) website

Do you wish to leave this site?

Are You a
Healthcare Professional?

The FDA approves a new indication for Otezla® (apremilast) Learn more about this treatment option for your patients
EXPLORE